CES 2023: Jackery Reveals the Revolutionary New Portable Solar Generators, Leading the Solar Power Generation Industry

LAS VEGAS, Jan. 5, 2023 /PRNewswire/ — Jackery, the global leader of innovative portable power and green outdoor energy solutions, has unveiled  its most innovative portable solar generators to complement the high-end Pro family – the 3000 Pro and 1500 Pro – at CES 2023 (booth No.8943), running from January 5-8, 2023 in Las Vegas.

The most influential tech event in the world, CES is ground zero for breakthrough technologies and global innovators and is where the world’s biggest brands discuss business and connect with prospective partners, and the sharpest innovators share their insights. At CES 2023, Jackery brings a lineup of new products and its awarded conceptual products to its booth. All the innovations highlight the brand’s stride in bringing green energy to people’s everyday life with its expertise in solar technology and a decade of solid experience in the industry.

Jackery’s latest portable Pro Family solar generator flagship product, the Solar Generator 3000 Pro, is the lightest and most compact in its class. With six SolarSaga 200W solar panels providing an optimal Ultra-Solar-Charging speed of 3-4 hours and wall-charge of 2.5 hours, it has a jaw-dropping 3024Wh of high-capacity power and 3000W AC output. Producing a maximum of 8500Wh per day, it can provide backup power for five days of outdoor adventures or home emergencies. Thanks to its unrivalled cooling system supported by high-precision chips and nine sensors, the 3000 Pro has 30 percent improved heat dissipation efficiency. Super quiet, only 30 decibels when charging in silent mode, and combining Bluetooth and Wi-Fi to communicate with and be controlled by mobile devices in real-time, the 3000 Pro redefines the outdoor lifestyle by providing an enhanced green power solution.

The Solar Generator 1500 Pro, that also features the Ultra-Charging System, is easily transportable making it ideal for entry-level outdoor enthusiasts. It bundles a high-capacity Jackery Explorer 1500 Pro Power Station with six cutting-edge magnetized foldable SolarSaga 200W solar panels that can be solar- or wall-charged in two hours. The 1500 Pro, with its 1512Wh capacity and maximum output power of up to 1800W, allows for the ultimate road trip experience with a fully equipped solution for clean energy capture, usability, and safety.

Both products, new to Jackery’s high-end Pro family, feature zero emissions, are shock-resistant and fire-retardant to UL 94V-0 standards and have industry-leading solar cells that contain Interdigitated Back Contact (IBC) technology that enables the 3000 Pro and 1500 Pro to maximize light absorption, including on cloudy days, early mornings, and late evenings. The pair show impressive and reliable discharging down to low temperatures of -20°C (-4°F) and Jackery’s intelligent Battery Management SystemTM (BMS) regulates and protects battery life and devices and offers twelve forms of protection to cover all kinds of unexpected scenarios, including over-current, short current, over-discharge, overcharge, over voltage, thermal protection, among others.

The two products, along with the 1000 Pro, launched at IFA 2022, and the 2000 Pro just named one of CES® Innovation Awards Honorees, have completed the lineup of Jackery’s high-end Pro family, broadening the Pro family’s power capacity options and allowing Jackery to provide more flexible solutions for more customers, especially van-lifers and outdoor enthusiasts. As a special treat for visitors interested in outdoor adventure, Jackery has invited renowned adventure athlete Tristan Hamm, nature lover and founder of Revived Outdoors, to have a workshop at Jackery’s booth on January 7. He will share his adventure stories with Jackery and his perspective on Jackery’s products.

About Jackery

Jackery, the world’s leading innovative portable power and green outdoor energy solution provider founded in California in 2012, is a global top-selling solar generator brand born with a vision to offer green energy to everyone, everywhere. Jackery launched the world’s first outdoor portable power stations in 2016 and developed the world’s first portable solar panels in 2018. Having introduced solar generators to the great outdoors, Jackery fulfills the power needs of every nature-lover, inspiring them to explore further and seek more extraordinary experiences than before.

Expanding its footprint from the US to Europe, Japan, and China, Jackery has sold more than 2 million units globally since 2018, with its products consistently selected as Best Sellers on Amazon. The brand has so far received 40 prestigious international design awards, including the Red Dot Design Award, the iF Design Award, the A’ Design Award and Competition, the Best of IFA Award and the CES Innovation Award.

Photo – https://mma.prnewswire.com/media/1977998/2.jpg
Photo – https://mma.prnewswire.com/media/1977073/image_5009324_34428792.jpg
Logo – https://mma.prnewswire.com/media/1877275/Jackery_Logo.jpg

Duck Creek to acquire Imburse Payments, a modern payments platform

Strategic acquisition will add digital, out-of-the box payments capabilities to Duck Creek’s comprehensive suite of SaaS solutions for P&C and general insurers

Boston, MA, Jan. 05, 2023 (GLOBE NEWSWIRE) — Duck Creek Technologies (NASDAQ: DCT) (“Duck Creek”), the intelligent solutions provider defining the future of property and casualty (P&C) insurance, today announced a definitive agreement to acquire Imburse Payments (“Imburse”), a Swiss-based modern payments platform.

Imburse’s cloud-native software-as-a-service (SaaS) payment solution is built for the insurance industry. The modern payments platform brings greater ease and efficiency into end-to-end insurance transactions. Imburse enables insurance carriers to quickly connect to the entire payments ecosystem at a lower cost, seamlessly integrate with existing finance infrastructure and processes, and manage multiple partners for collections and disbursements, all in one place. The platform is consumer friendly and provides policyholders with both an easy-to-use, flexible payments experience and the ability to quickly and securely direct payments.

As part of Duck Creek, Imburse will continue to serve its existing client base and markets, while accelerating expansion plans for new clients across Europe and into North America and Asia-Pacific. The Imburse platform will continue to be available on a stand-alone basis and will also be fully integrated with Duck Creek’s suite of technology solutions, further enabling carriers’ digital transformation goals with modern tools.

“Imburse has developed a great product for the global insurance industry that is not only easy to integrate and implement, but also gives carriers incredible flexibility and payment choices,” said Mike Jackowski, CEO of Duck Creek Technologies. “Imburse has a strong team that embodies Duck Creek’s core values. They have deep expertise across the payments ecosystem and will help to broaden Duck Creek’s insurance industry leadership.”

“Being part of Duck Creek will further accelerate our mission to simplify how businesses around the world access the global payments ecosystem,” said Oliver Werneyer, CEO of Imburse. “We are excited to be part of Duck Creek and to work jointly to deliver modern technology innovations that transform the insurance industry for the future.”

The acquisition remains subject to customary closing conditions and is expected to close during the second fiscal quarter of 2023.

Conference Call Information

Duck Creek Technologies will host a conference call today, January 5, 2023, at 5:00 p.m. (Eastern Time) to discuss Duck Creek’s financial results and business outlook, as well as the proposed acquisition of Imburse Payments. A live webcast of the call will be available on the “Investor Relations” page of the Duck Creek’s website at https://ir.duckcreek.com/. To access the call by phone, please go to this link (registration link), and you will be provided with dial in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. A replay of the webcast will also be available for a limited time at https://ir.duckcreek.com/.

About Imburse Payments

Imburse is a modern payments platform built for insurers. Via a single connection, directly or through a current core system provider, insurance carriers can access the entire global payment ecosystem to collect or pay-out using any technology, any provider, in any market.

About Duck Creek Technologies

Duck Creek Technologies (NASDAQ: DCT) is the intelligent solutions provider defining the future of the property and casualty (P&C) and general insurance industry. We are the platform upon which modern insurance systems are built, enabling the industry to capitalize on the power of the cloud to run agile, intelligent, and evergreen operations. Authenticity, purpose, and transparency are core to Duck Creek, and we believe insurance should be there for individuals and businesses when, where, and how they need it most. Our market-leading solutions are available on a standalone basis or as a full suite, and all are available via Duck Creek OnDemand. Visit www.duckcreek.com to learn more. Follow Duck Creek on our social channels for the latest information – LinkedIn and Twitter.


Drake Manning
Duck Creek Technologies

Carley Bunch
Duck Creek Technologies

Michael Sharp
Imburse Payments

GlobeNewswire Distribution ID 8724246

iHerb Top Wellness Trends in 2023

Dr. Michael Murray, N.D. forecasts the 2023 wellness trends on the rise on iHerb’s popular blog

PASADENA, Calif., Jan. 5, 2023 /PRNewswire/ — iHerb, the largest eCommerce platform, dedicated to vitamins, minerals, and supplements has tapped Dr. Michael Murray, N.D. – one of the leading authorities in dietary supplements, and natural products – to share his insights for the top health and wellness trends likely to gain popularity in 2023. The full wellness prediction can be found on iHerb’s blog, the go-to guide featuring advice from credentialed contributors on what’s new and next for living well.

iHerb Logo
Trend #1: Changing Consumer Health & Wellness Focus

Immune health has been a key focus since the onset of the COVID-19 pandemic, but recent surveys indicate other priorities are rising as well. In one survey of over 5,000 consumers from seven countries, the top concerns were sleep quality and stress, as well as brain health and function. In the blog post, you will find Dr. Murray’s recommendations for the top supplements for each of these health concerns.

Trend #2: More People Are Set To Discover the Power of Protein

Market data shows that the protein powder and amino acids segment is the fastest-growing sector in the supplement category. It is not only the increasing number of sports enthusiasts and bodybuilders fueling this growth, but also consumers purchasing collagen protein products to help promote skin health and beauty from within. Dr. Murray notes that Collagen leads as the fastest-growing protein choice, with consumers also purchasing more and more vegan protein (pea, hemp, pumpkin, soy, rice, etc.) and whey, casein, and egg protein powders.

Trend #3: Non-Pill Forms of Supplements Will Grow in Popularity

Traditional tablets and capsules will continue to be a top choice, but consumers are also increasingly looking to non-pill alternatives. According to Nutrition Business Journal, in 2021, more than 60% of the purchases of dietary supplements were non-pill forms like gummies, chews, powders & tablets, exceeding sales of pills for the first time. Within the article, Dr. Murray explains why gummy supplements, in particular, are at the head of this growth, and how we can expect them to continue to rise – with the most significant trend being the growth in vegan gummies specifically.

Trend #4: Mushroom Products Are Blooming

The global health mushroom market is estimated to be worth over $25 billion and is expected to grow over 10% yearly for the next eight years. This growth represents the significant increase in the popularity of functional mushrooms as both food and dietary supplements due to their numerous health benefits. Dr. Murray predicts that Chaga, Cordyceps and Turkey Tail will surge in popularity, in addition to well known shiitake and reishi, and why within his trend forecast.

Trend #5: Sustainable Hydration Products Are Moving Upwards

Another emerging trend that Dr. Murray notes is the increase in the popularity of effervescent electrolyte mixes used to enhance water and promote hydration, which he cites in the blog as one of the fastest-growing types of dietary supplements. These hydration products are available in both tablets and powdered drink mixes, and serve as alternatives to ready-to-drink electrolyte hydration drinks in wasteful, single use plastic bottles. Historically, athletes have used electrolyte drinks and supplements to help recover, and consumers across the board are now using them to seamlessly deliver functional ingredients as well.

More healthy living guidance from iHerb’s team of health expert contributors can be found at www.iherb.com/blog. Launched in 2017, iHerb’s blog has over 1,500 articles from over 100 credentialed contributors, from M.D.s and N.D.s to Dermatologists, Registered Dietitians, Certified Strength and Conditioning Specialists, and more. Professionally translated into 14 languages and having generated over 10 million visitors in 2022, the iHerb’s blog is an excellent resource for all things health and wellness.

About iHerb: We are the largest e-commerce retailer dedicated to the Vitamins, Minerals, Supplements, or VMS, category, with a growing presence in other areas of consumer health and wellness. Trusted by millions in over 185 countries, we offer a curated portfolio of branded and innovative third-party and proprietary products at the best possible value, conveniently delivered directly to our customers. https://www.iherb.com/

Logo – https://mma.prnewswire.com/media/742063/iHerb_Logo.jpg

‫نادين شكر رئيسة تنفيذية لشركة Securrency الرائدة في مجال الابتكار في التكنولوجيا المالية

شكر ستقود المرحلة التالية من النموّ مع تسريع  Securrency تسويق تكنولوجيا الأصول الرقمية القائمة على الامتثال للمؤسسات المالية الدولية

واشنطن، 5 يناير 2023 / PRNewswire / – أعلنت اليوم شركة Securrency الرائدة في مجال تطوير التكنولوجيا المالية والتنظيمية القائمة على البلوك تشين عن انضمام نادين شكر إلى الشركة بمنصب الرئيسة التنفيذية اعتبارًا من 9 يناير 2023.


وتتمتّع السيدة شكر بخبرة لافتة في مجال الخدمات المالية والتكنولوجيا والأسواق وستستخدمها، إلى جانب تكنولوجيا Securrency الرائدة، لنشر الحلول المبتكرة في الأسواق على نطاق دوليّ. وتُعتبر السيدة شكر من أقوى النساء في المجال الماليّ ، ومن أبرز داعمي استخدام التكنولوجيا لإحداث نقلة نوعيّة في الخدمات المالية. كما تتفرّد بخبرة تزيد عن 30 عامًا في مجال إدارة الثروات العالمية والأصول، وشغلت مؤخرًا منصب نائبة الرئيس التنفيذي ورئيسة State Street Digital ، حيث تولّت بناء وقيادة الفريق الذي يساعد State Street والمستثمرين المؤسسيين والمنظّمين في عمليّة انتقال البنك إلى الاقتصاد الرقمي الحديث. كذلك، قادت السيدة شكر شركة State Street Global Markets ، حيث أشرفت على منصة التداول والمنتجات والعمليات فيها، مما ساهم في توفير حلول ناجحة للعملاء. وقبل عملها في State Street ، تولّت منصب رئيسة العمليات الدولية في قسم إدارة الثروات والأصول العالمية في Manulife وقادت فرق خدمات الأصول العالمية في BNY Mellon .

و إضافة إلى دورها القياديّ في State Street Digital ، شغلت السيدة شكر منصب عضو في مجلس إدارة Securrency  منذ عام 2021. ويأتي تعيينها كرئيسة تنفيذية للشركة ليؤكّد على الأهمية المتزايدة لامتثال ترميز الأصول، وقابلية التشغيل البينيّ، والتمويل اللامركزي المؤسّسي بالنسبة إلى مستقبل التمويل العالمي.

وسيتيح تعيين السيدة شكر لمؤسّس Securrency ، دان دوني، الذي شغل منصب الرئيس التنفيذي للشركة والمهندس المسؤول منذ إنشائها، التركيز على الابتكار وتطبيق التكنولوجيا وتسويقها من خلال مواصلة عمله كالرئيس التنفيذي للتكنولوجيا في الشركة. ويُعتبر السيد دوني أحد أبرز قادة الفكر في مجال التمويل اللامركزي والبلوك تشين. وسيساهم تركيزه على هذا المجال في تسريع نموّ حصة Securrency في السوق من البنية التحتية للخدمات المالية المدعومة بالبلوك تشين.

و قالت نادين شكر، الرئيسة التنفيذية الجديدة لشركة Securrency : “بلغ قطاع الخدمات المالية مرحلة مفصليّة مع ترميز أصول العالم الحقيقي المنظّمة وأتمتة العمليات المالية القديمة باستخدام تكنولوجيا البلوك تشين الفعّالة. لقد قام فريق Securrency بعمل مميّز من خلال تطوير أكثر التقنيات المتاحة في السوق فعالية. وبصفتي الرئيسة التنفيذية الجديدة، تتمثّل أولويّتي في العمل على تسريع التسويق التجاري لأساس ذكاء الأصول الرقمية وقابلية التشغيل البينيّ لصالح كبرى المؤسسات المالية والمنظومة الدولية. إنّ دان دوني صاحب رؤية واعدة ومبتكر حقيقي في هذا القطاع، وأتطلّع شخصيًا للعمل معه عن كثب ومع باقي الفريق لإنشاء أسواق الأصول الرقمية العالمية المستقبلية.”

من جهته، قال دان دوني، الشريك المؤسّس والرئيس التنفيذي للتكنولوجيا في Securrency : “نادين من القادة الاستثنائيين وقد حظيت Securrency بفرصة الاستفادة من خبرتها الواسعة في القطاع المالي كعضو في مجلس الإدارة والآن كرئيسة تنفيذية جديدة. فهي على اطلاع على كامل عمليات سوق رأس المال وتشاركني شغفي بالابتكار حيث يحرص كلانا على تعزيز كفاءة الأسواق المالية وتسهيل الوصول إليها. و تتمتّع نادين بنظرة ثاقبة تدرك نت خلالها الإصلاحات المطلوبة وكذلك أهمية تكنولوجيتنا، وأتطلّع للعمل معها مع تركيزنا على تطوير حلول تجمع بين التمويل التقليدي واللامركزي.”

من جانبه، قال جوناثان سًتاينبرغ، الرئيس التنفيذي لشركة WisdomTree : “يعتمد مستقبل القطاع المالي على التطوير الرقمي القائم على الامتثال والتنظيم، ولطالما دعمت نادين مسيرة التطوّر هذه. فمن خلال عملي معها كعميل ورائد في القطاع، لفتتني خبرتها الواسعة في دمج التكنولوجيا التنظيمية والأصول الرقمية وقناعتها الراسخة بأنّ تكنولوجيا Securrency ستمهّد الطريق للتمويل اللامركزيّ المؤسسي. ولا بدّ لي في هذه المناسبة من تهنئة نادين ودان وفريق عمل Securrency بأكمله على هذه الخطوة الجريئة التي اتخذتها الشركة.”

نبذة عن Securrency

Securrency شركة تكنولوجيا مالية وتنظيمية تستخدم تقنية البلوك تشين المؤثّرة لتوفير بنية تحتية للأصول الرقمية لإنشاء أسواق وتحفيز السيولة العالمية. وتقود Securrency التغيير في قطاع الخدمات المالية من خلال إطار عمل Compliance Aware Token® الحاصل على براءة اختراع والقابل للتشغيل البينيّ بالكامل والذي يربط بين المنصات المالية التقليدية وشبكات الجيل التالي من البلوك تشين. ومن بين العملاء والمستثمرين الإستراتيجيين للشركة: WisdomTree  (المدرجة في بورصة نيويورك تحت الرمز WT)، وState Street (المدرجة في بورصة نيويورك تحت الرمز STT)، أبوظبي كاتاليست بارتنرز، و“دسربت أي دي”، منصّة المشاريع التابعة لـ “القابضة” (ADQ). لمزيد من المعلومات، الرجاء زيارة الموقع http://securrency.comومتابعتنا على لينكدإن وتويتر.


AUM Biosciences Receives U.S. FDA Rare Pediatric Disease Designation for AUM302 for Treatment of Neuroblastoma

AUM302 is potentially eligible to receive a rare pediatric disease priority review voucher at the time of marketing approval

SINGAPORE and BETHESDA, Md., Jan. 05, 2023 (GLOBE NEWSWIRE) — AUM Biosciences Pte. Ltd. (“AUM”), a global clinical-stage biotech company focused on discovering and developing precision oncology therapeutics, announced today that the U.S. Food and Drug Administration (FDA) has granted a Rare Pediatric Disease Designation (RPDD) for its product candidate, AUM302, a potential first-in-class oral kinase inhibitor that targets not only PI3K, but also key resistance mechanisms such as PIM and mTOR, for the treatment of neuroblastoma. In November 2022, the FDA granted Orphan Drug Designation (ODD) for AUM302.

“Neuroblastoma is the third most common pediatric cancer, and more than 90 percent of children diagnosed are under five years old. The RPD highlights the urgency for treatment of this devastating disease where AUM302 could potentially emerge as a breakthrough therapy for children,” said Vishal Doshi, Chairman and CEO of AUM Biosciences. “This timely addition to our recent orphan drug designation granted by the FDA reinforces our commitment to developing therapeutic candidates that are accessible, safe, effective, and affordable for patients. We expect to file an Investigational New Drug (IND) application with the FDA for our first-in-human clinical trial in mid-2023.”

The FDA grants RPDD for serious and life-threatening diseases that primarily affect individuals from birth to 18 years old and fewer than 200,000 persons in the United States. If a New Drug Application (NDA) for AUM302 is approved, AUM Biosciences is potentially eligible to receive a rare pediatric disease priority review voucher. This voucher may be sold or transferred to a third-party pharmaceutical company who can exercise it to reduce FDA approval timelines from six to nine months on an internal drug program.

On October 20, 2022, AUM and Mountain Crest Acquisition Corp. V (Nasdaq: MCAG) (“Mountain Crest”), a publicly traded special purpose acquisition company formed in Delaware, whose management team has an impressive pedigree of successful SPAC transactions, announced that they have entered into a definitive business combination agreement (the “Agreement”). Upon closing of the transaction, the combined company will operate under a holding entity, AUM Biosciences Limited, a Cayman Islands exempted company (“Holdco”) and intends to trade on the Nasdaq Stock Market under the ticker symbol AUMB.

About AUM302
AUM302 is a potential first-in-class oral kinase inhibitor rationally designed to uniquely combine pan-PIM kinase, pan-PI3K and mTOR inhibition in a single agent. This multi-targeting approach has been engineered into a single molecule that has the potential to inhibit multiple key intracellular pathways, increasing its ability to inhibit cancer cell growth and prevent resistance emergence. In early studies to date, AUM302 has shown promise with good tolerability and favourable drug properties. AUM302 is a unique multi-targeted cancer therapeutic that targets not only PI3K, but also key resistance mechanisms such as PIM and mTOR. AUM302 is a single molecule therapeutic designed to optimize inhibition of these key pathways.

About Neuroblastoma
Neuroblastoma is the most common extracranial solid tumour in childhood. More than 650 cases are diagnosed each year in the United States. The prevalence is about 1 case per 7,000 live births. The incidence is 10.54 cases per 1 million per year in children younger than 15 years. About 37% of patients are diagnosed as infants, and 90% are younger than 5 years at diagnosis, with a median age at diagnosis of 19 months.

About AUM Biosciences
AUM is a global clinical-stage oncology company focused on advancing a pipeline of precision oncology therapeutics designed to deploy multi-faceted inhibition strategies to reverse cancer resistance. AUM is advancing a broad portfolio of precision oncology therapeutics. AUM001 is a selective and synergistic MNK inhibitor as shown in current studies and expected to begin Phase 2 enrolment in the first quarter 2023. AUM601 is a promising therapy for tropomyosin receptor kinase (TRK) fusions and mutations within the kinase domain and is on track to enter Phase 2 planning. AUM302 is a potentially first-in-class macrocyclic oral kinase inhibitor rationally designed small molecule to uniquely combine pan-PIM kinase, pan-PI3K and mTOR inhibition in a single agent. Comprised of industry veterans with decades of research and development experience, the AUM leadership has an extensive track record of selecting distinctive early-stage assets, successfully exiting virtual biotech models, and has contributed to over 50 INDs and over 150 oncology clinical trials, and development of several currently marketed oncology treatments with annual peak sales up to $3 billion.

About Mountain Crest
Mountain Crest Acquisition Corp. V (Nasdaq: MCAG) is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.

This press release shall not constitute a solicitation of a proxy, consent, or authorization with respect to any securities or in respect of the proposed business combination. This press release shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or an exemption therefrom.

Important Information About the Proposed Business Combination and Where to Find It
In connection with the proposed business combination, AUM, Mountain Crest and/or a successor entity of the transaction intends to file relevant materials with the SEC, including a registration statement on Form F-4 containing a proxy statement/prospectus (the “Registration Statement”). The Registration Statement will include a proxy statement/prospectus to be distributed to holders of Mountain Crest’s common stock in connection with Mountain Crest’s solicitation of proxies for the vote by Mountain Crest’s stockholders with respect to the proposed transaction and other matters as described in the Registration Statement, as well as the prospectus relating to the offer of securities to be issued to AUM’s stockholders in connection with the proposed business combination. After the Registration Statement has been filed and declared effective, Mountain Crest will mail a definitive proxy statement, when available, to its stockholders. Copies of these documents may be obtained free of charge at the SEC’s website at www.sec.gov. Stockholders of Mountain Crest are urged to read the Registration Statement and the other relevant materials when they become available before making any voting decision with respect to the proposed business combination because they will contain important information. The information contained on, or that may be accessed through, the website referenced in this press release is not incorporated by reference into, and is not a part of, this press release.

Participants in the Solicitation
Mountain Crest and its directors and executive officers may be deemed participants in the solicitation of proxies from Mountain Crest’s stockholders with respect to the business combination. A list of the names of those directors and executive officers and a description of their interests in Mountain Crest will be included in the Registration Statement for the proposed business combination and be available at www.sec.gov. Additional information regarding the interests of such participants will be contained in the Registration Statement for the proposed business combination when available. Information about Mountain Crest’s directors and executive officers and their ownership of Mountain Crest common stock is set forth in Mountain Crest’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as modified or supplemented by any Form 3 or Form 4 filed with the SEC since the date of such filing. Other information regarding the interests of the participants in the proxy solicitation will be included in the Registration Statement pertaining to the proposed business combination when it becomes available. These documents can be obtained free of charge from the sources indicated above.

AUM and its directors and executive officers may also be deemed to be participants in the solicitation of proxies from the stockholders of Mountain Crest in connection with the proposed business combination. A list of the names of such directors and executive officers and information regarding their interests in the proposed business combination will be included in the Registration Statement for the proposed business combination.

Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Mountain Crest’s and AUM’s actual results may differ from their expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, Mountain Crest’s and AUM’s expectations with respect to future performance and anticipated financial impacts of the proposed business combination, the satisfaction of the closing conditions to the proposed business combination, and the timing of the completion of the proposed business combination.

These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside Mountain Crest’s and AUM’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the occurrence of any event, change, or other circumstances that could give rise to the termination of the Agreement; (2) the outcome of any legal proceedings that may be instituted against Mountain Crest and AUM following the announcement of the Agreement and the transactions contemplated therein; (3) the inability to complete the proposed business combination, including due to failure to obtain approval of the stockholders of Mountain Crest and AUM, certain regulatory approvals, or satisfy other conditions to closing in the Agreement; (4) the occurrence of any event, change, or other circumstance that could give rise to the termination of the Agreement or could otherwise cause the transaction to fail to close; (5) the impact of the COVID-19 pandemic on AUM’s business and/or the ability of the parties to complete the proposed business combination; (6) the inability to obtain the listing of Holdco’s ordinary shares on Nasdaq following the proposed business combination; (7) the risk that the proposed business combination disrupts current plans and operations as a result of the announcement and consummation of the proposed business combination; (8) the ability to recognize the anticipated benefits of the proposed business combination, which may be affected by, among other things, competition, the ability of AUM to grow and manage growth profitably, and retain its key employees; (9) costs related to the proposed business combination; (10) changes in applicable laws or regulations; (11) the possibility that Mountain Crest or AUM may be adversely affected by other economic, business, and/or competitive factors; (12) risks relating to the uncertainty of the projected financial information with respect to AUM; (13) risks related to the organic and inorganic growth of AUM’s business and the timing of expected business milestones, including but not limited to the safety and/or efficacy of AUM302, or AUM’s inability to obtain regulatory approval of any product; (14) the amount of redemption requests made by Mountain Crest’s stockholders; and (15) other risks and uncertainties indicated from time to time in the final prospectus of Mountain Crest for its initial public offering and the Registration Statement relating to the proposed business combination, including those under “Risk Factors” therein, and in Mountain Crest’s other filings with the SEC. Mountain Crest cautions that the foregoing list of factors is not exclusive. Mountain Crest and AUM caution readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Mountain Crest and AUM do not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in their expectations or any change in events, conditions, or circumstances on which any such statement is based.

For AUM Biosciences Pte. Ltd.
Mr. Vishal Doshi
10 Anson Road, 24-16 A/B, Singapore, 079903

ICR Westwicke
Stephanie Carrington
T: (646) 277-1282

FINN Partners
Glenn Silver
T: (973) 818-8198

Verlynn Heng

GlobeNewswire Distribution ID 8723873